Haemonetics Corp: BTIG raises target price to $110 from $96

BTIG has revised its price target for Haemonetics Corp (NYSE: HAE), raising it to $110 from the previous $96, according to recent reports. The adjustment follows strong performance metrics from the company, which have prompted the firm to maintain a positive outlook on its future prospects. The updated target reflects an increased confidence in Haemonetics’ operational performance and market positioning. Investors are advised to consider the firm’s rationale, which is based on recent financial results and strategic developments. While the firm has not indicated a change in its overall rating, the price target increase suggests a favorable assessment of the company’s trajectory. Market participants are encouraged to review the firm’s full analysis for a comprehensive understanding of the rationale behind the adjustment. As always, investors should conduct their own due diligence and consider broader market conditions before making investment decisions.